Drug Profile
Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate - Xenikos
Alternative Names: HENO 3; MabCD3-dgA/CD7-dgA; T-GuardLatest Information Update: 29 Jun 2022
Price :
$50
*
At a glance
- Originator Radboud-University-Nijmegen-Medical-Centre
- Developer Xenikos
- Class Drug conjugates; Immunotoxins; Lectins; Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Protein synthesis inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Graft-versus-host disease
Highest Development Phases
- Phase III Graft-versus-host disease
Most Recent Events
- 27 Jun 2022 Phase-III clinical trials in Graft-versus-host disease (In adults, In the elderly) in Croatia, Italy (IV) (EudraCT2021-000343-53)
- 27 Jun 2022 Phase-III clinical trials in Graft-versus-host disease (In adults, In the elderly) in France, Belgium (IV) (NCT04934670)
- 27 Jun 2022 Phase-III clinical trials in Graft-versus-host disease (In adults, In the elderly) in Netherlands, Germany, Spain (IV) (NCT04934670) (EudraCT2021-000343-53)